relapse

People with neuromyelitis optica spectrum disorder (NMOSD) often have other co-occurring autoimmune diseases and those who do have a significantly higher risk of a relapse than people with NMOSD alone, a study in Portugal suggests. Long-term disability outcomes didn’t differ between the two groups, however, suggesting “appropriate treatment may…

Nearly all neuromyelitis optica spectrum disorder (NMOSD) patients who start taking Enspryng (satralizumab) are free of relapses after six months, according to interim data from an ongoing post-marketing surveillance study in Japan. With a relapse rate of only 5% over six months, the findings were “comparable or lower…

Most neuromyelitis optica spectrum disorder (NMOSD) patients who start taking Enspryng (satralizumab) remain free of relapses for at least a year, with some being able to stop treatment with oral glucocorticoids, according to a study of real-world data. The findings are consistent with those of SAkuraStar (NCT02073279)…

A severe attack or a higher annual relapse rate before starting azathioprine or mycophenolate mofetil (MMF) was associated with a poor response in people with neuromyelitis optica spectrum disorder (NMOSD), a small study shows. An unsatisfactory response to either treatment, defined as a severe relapse or two or more…

A history of smoking is associated with poorer recovery from disease relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a study reports. Findings indicate that patients who smoke or are past smokers are more likely to have neurological lesions that persist months after the relapse, and that these…

The rate of disease onset or relapse of neuromyelitis optica spectrum disorder (NMOSD) after a SARS-CoV-2 infection — the virus that causes COVID-19 — is extremely low, at about 1 in 50 million, according to a worldwide review study. The occurrence of NMOSD was even lower, at 1 in…

People who are younger at the onset of neuromyelitis optica spectrum disorder (NMOSD) and those with multiple organ involvement at the first attack by the disease have a higher risk of relapse during treatment with traditional immunosuppressants, a study showed. A reduction in the levels of antibodies against…

Ofatumumab, a medication approved for multiple sclerosis (MS), effectively prevented relapses and disability progression in a 67-year old woman with neuromyelitis optica spectrum disorder (NMOSD) who failed to respond to rituximab, a Chinese case report described. Both ofatumumab and rituximab — often used off-label in NMOSD — promote the…

Women with neuromyelitis optica spectrum disorder (NMOSD) who received immunosuppressive treatment during pregnancy or were at least 32 years old when they conceived may be at a lower risk of pregnancy-associated relapses, a systematic review study has found. Data also showed the risk of relapse is highest in the…

An analysis of pharmacological data supports the observed clinical efficacy of Soliris (eculizumab) in significantly reducing relapses in patients with neuromyelitis optica spectrum disorder (NMOSD) given the therapy in the PREVENT Phase 3 clinical trial. At its approved dose, Soliris led to rapid, sustained, and complete suppression…